Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Boraso, Sabrina (2008) Patologia emocoagulativa e suo trattamento in corso di sepsi. [Tesi di dottorato]

Full text disponibile come:

[img]
Anteprima
Documento PDF
4Mb

Abstract (inglese)

The host response to infection involves soluble mediators ( components of flogosis, clotting factors) and cells(platelets, endothelial cells and monocites) and is a continuum of complex and very organized chain reactions that have as objective the elimination of pathogenic threat, and the restitution ad integrum of the host.
However if the response is excessive , the host response turn on its bearer and causes the organ dysfunction.
In sepsis there is a strong cross-talk between flogosis and coagulation.
In septic patients the primary activation of haemostasis is associated to thrombocytopenia with a variable incidence from 36%-60%.
There is an attenuation of anticoagulant mechanism, including P C; AT, and the fibrinolitic way.
In patients affected by two organ failure septic shock, the recommended therapy comprise the use of activated recombinant protein c. We analyzed the effect of activated recombinant protein c in a limited group of patients in ICU on coagulation cascade. In particular we studied coagulation parameter variation of septic patients. Despite a deep knowledge on coagulation cascade, poor information are available on VWF role on septic coagulation modifications.
Four patients were enrolled in our study that lasted 28 days.
Our study suggest that high VWF:Ag e VWF:CBA levels remain elevated during all the period evaluated. Moreover thrombocytopenia is not correlated to VWF levels. Clinical features are quite different from Moskowitz Syndrome characterized by platelets number decrease associated with high molecular weights consumption as cause-effect.
VWF level trend probably correlates with endothelium injury. In fact we can assume that persistent high levels of VWF confirm a continuous and severe endothelium injury causing a multiorgan failure. VWF dosage trend may be an important prognostic index.
Future improvements may include propeptide and ADAMTS13 dosage, though VWF multimers distribution does not seem to be well-matched with significant deficits of this metalloproteasi.


Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Giron, Giampiero
Dottorato (corsi e scuole):Ciclo 20 > Corsi per il 20simo ciclo > FARMACOLOGIA E TOSSICOLOGIA, TERAPIA RIANIMATIVA E INTENSIVA
Data di deposito della tesi:31 Gennaio 2008
Anno di Pubblicazione:31 Gennaio 2008
Parole chiave (italiano / inglese):SEPSIS, COAGULATION, VWF
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/41 Anestesiologia
Struttura di riferimento:Dipartimenti > Dipartimento di Farmacologia ed Anestesiologia "E. Meneghetti"
Codice ID:974
Depositato il:22 Ott 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

(1)Aird W. C. Sepsis e coagulation. Crit Care Clin 21 (2005) 417-431 Cerca con Google

(2) Aird W.C. The hematologic system as a marker of organ dysfunction sepsis. Mayo Clin Proc 2003;78:869-881. Cerca con Google

(3) Mori M., kudo H., Yoshitake S transient EDTA-dependentpseudothrombocytopenia in patiens with sepsis. Intensive Care Med 2000; 26:218-220. Cerca con Google

(4) Stephan F., Cheffi M.A., Kaplan C.. Autoantibodies against platelet glycoproteins in critically ill patiens with thrombocytopenia. Am J Med 2000; 108: 554-60 Cerca con Google

(5) Francois B., Trimoreau F., vignon P. Thrombocytopenia in sepsis syndrome : role of hematophagocytosis and macrophage colony-stimulating factor. Am J Med 1997; 103: 114-120. Cerca con Google

(6) Warkentin T.E.,Aird W.C., Rand J.H.. Platelet-endothelial interections: sepsis, HIT, and antiphosholipid-syndrome. Hematology 2003;:497-519. Cerca con Google

(7) Sawaki D. MD, Yoshitaka O., et all. A case of Heparin- Inducee Thrombocytopenia with sepsis and congestive Heart failure. Circ J 2004;68:1215-1218. Cerca con Google

(8) Vanderschueren S., De Weerdt A.. Thrombocythopenia and prognosis in intensive care. Critical Care Med 2000; 28: 1871-1876.ù Cerca con Google

(9) Gary T., Kinasewitz M.D., et all. Prognostic value of simple envolving DIC score in patiens with severe sepsis. Crit Care Med 2005; 33:2214-2221. Cerca con Google

(10) Levi M. Platelets at a crossroad of pathogenic pathways in sepsis. J Thromb Haemost 2004; 2:2094-5. Cerca con Google

(11) Levi M. Disseminated Intravascular Coagulation: What’s News? Critical Care Clinics 2005; 21: 449-467. Cerca con Google

(12) Yaguchi A., Lobo F. L. M., Vincent J. L., et all. Platelet function in sepsis. J Thromb Haemost 2004;2: 2096-2102. Cerca con Google

(12 a) Cowan DH. Platelet aggrgation as a sign of septicemia in thermal injury. A prospective study. Jama 1976; 235:1230-4 Cerca con Google

(13) Levi M. Platelet in sepsis. Hematology 2005;10 (s 1): 129-31. Cerca con Google

(14) Bernard G.F., Vicent J.L., Laterre P.F.. Efficacy and safety of recumbinant human activated protein C for severe sepsis. NEJM 2001; 344:699-709. Cerca con Google

(15) Yan S.B., Helterbrand J.D., Hartman D.L.. Low levels of protein C are associated with poor outcame in severe sepsis. Chest 2001; 120:915-22. Cerca con Google

(16)White B., Perry D.. Acquired antithrombin deficiency in sepsis. Br J haematol 2001, 112: 26- 31. Cerca con Google

(17) Eisele B., Lamy M..Antithrombin III in patiens with severe sepsis: a randomized, placebocontrolled, double-blind multicenter trial plus a meta-analysis on all randomized, lacebocontrolled, double-blind trials with Antithrombin III in severe sepsis. Intesive Care Med 1998;24:663-72. Cerca con Google

(18) Opal S.M., fisher Jr C. J., Dhainaut J.F.. Confirmatory IL-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trials. Crir Care Med 1997;25:1115-24. Cerca con Google

(19) Bauer K.A., Rosemberg R. D. Role of ATIII as a regulator in vivo coagulation. Semin Hematol 1991;28(1):10-8. Cerca con Google

(20) Wiel E., Vallet B, et all .The Endothelium in intensive care. Crit care Clin 2005;21:403-413 Cerca con Google

(21) van Hinsebergh V.W. The endothelium : vascular control of haemostasis. Eur J Obstrt Gynecol Reprod Biol 2001;95(2):198-201. Cerca con Google

(22) Riewald M., Ruf W. Science review:role of coagulation protease cascade in sepsis. Crit Care 2003;7:123-9. Cerca con Google

(23) Leclerc J., et all. A single endotoxin injection in the rabbit causes prolunged bood vessel dysfunction and a procoagulant state. Crit Care Med 2000; 28:3672-3678. Cerca con Google

(24) Wang P., Wood T.J.et all. Inhibition of the biological activity of TNF mantains vascular endothelial cell function during hyperdynamic sepsis. J Trauma 1996; 40: 694-71. Cerca con Google

(25) Bauer P.R. Microvascular responses to sepsis: clinical significance. Pathophysiology 2002; 8:141-148. Cerca con Google

(26) Sessler C., Windsor A., et all. Circulating ICAM-1 is increased in septic shock. Am J Respir Crit Care Med 1995;151:1420-27. Cerca con Google

(27) Matsukawa A., Lukacs N. W., et all. Mice genetically lacking endothelial selectins are esistent to the lethality in septic peritonitis. Exp Mol Pathol 2002;72:68-76. Cerca con Google

(28) Vincent J.L., De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care 2005; 9 (suppl): S9-S-12. Cerca con Google

(29) Vallet B. Bench-to-bedside review: Endothelial cell dysfunction in severe sepsis:role in organ dysfunction? Critical Care 2003; 7:130-8. Cerca con Google

(30) Nieuwland R., Berckmans R.J., Mc Gregor S., et all. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;1. 95 (3):930-935. Cerca con Google

(31) Ras O., Shet A., Bach R.R. Induction of microparticle-and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103: 4545-4553. Cerca con Google

(32 ) Riewald M., Ruf W. Science review:role of coagulation protease cascade in sepsis. Crit Care 2003;7:123-9. Cerca con Google

(33) Ruf W., Dickinson C.D. Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med 1998;8:350-56. Cerca con Google

(34) Ruf W., Edgington T.S. Structural biology of TF, the initiator of thrombogenesis in vivo. FASEB J 1994;8: 385-90. Cerca con Google

(35) Hermans P. W., Hibberd M. L., booy R.,et all. 4G/5G promoter polymorphism in the plasminogen-activator-inibitor-1 gene and outcome of meningococcal desease. Meningococcal Reserch Group. Lancet 1999; 354:556-60. Cerca con Google

(36) Dempfle C. E. Coagulopathy of sepsis. Thromb Haemost 2004; 91: 213-24 Cerca con Google

(37) Ratnoff O.D., Nebehay W.G.. Multiple coagulative defects in patiens with the Waterhouse- Friderihsen syndrome. Ann Inter Med 1962; 56: 627-630. Cerca con Google

(38) Shimamura K., Oka K., Nakazawa M.. Distribuition patterns of microthrombi in DIC. Arch Pathol Lab Med 1983; 107:543-7. Cerca con Google

(39) Levi M., Cate H. Dissiminated intravascular coagulation. NEJM 1999;19:586-592. Cerca con Google

(40) Iba T., Kidokoro A., Fukunaga M., et all. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005;1:25-29 Cerca con Google

(41) Dhainaut JF. ISTH score. Thromb Haemost 2004:2:1924-33 Cerca con Google

(42) Taylor F.B., Wada H., Kinasewitz G. Descriptionof compensated and uncompensed disseminated itravascular coagulation (DIC) responses (non-overt DIC) in baboon models of intravenous and intraperitoneal Escherichia Coli sepsis and human models of endotoxiemia: toward a better definition of DIC. Crit Care Med 2000; 28 (9suppl):S12-9. Cerca con Google

(43) Ely E.W., Laterre P.F., Angus D.C., et al. Drotrecogin alfa (activaed) administration across clinically important subgrups of patiens with severe sepsis. Crit Care med 2003; 31(1):12-9. Cerca con Google

(44 )Taylor FB. Toward definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86(5):1327-30. Cerca con Google

(44 a) Regan DH. Defibrination syndrome: changing concepts and recognition of the low grade form. Am J Med Sci 1973;266(2):84-91 Cerca con Google

(45) Perera L., Foley C., et all. Modelling zymogen PC. Biophisical Journal 2000; 79:2925-2943. Cerca con Google

(46) Foster D., Yoshitake s.,et all. The nucleotide sequence of gene for human protein C. Proc Natl Acad Sci. USA: 82:4673-77. Cerca con Google

(47) Dahlback B., Hildebrand B. Inherted resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci. USA. 91:1396-1400. Cerca con Google

(48) Yegneswaran S., Wood G.M., et all. Protein S alters location of the activated protein C above the membrane surface. A fluorescenze resonance energy transfert study of topography. J Biol. Chem.1997:272:25013-25021. Cerca con Google

(49) Jane S.M., Hau L.,et all. Regulation of APC by factor Xa. Blood Coagul Fibrinolysis 1991; 2:723-729. Cerca con Google

(50) Zolton R.P, Seegers W.H. Autoprotrombina II-A:trombin removal and mechanism of induction fibrinolysis. Thromb Res !973;3:23-33. Cerca con Google

(51) Esmon C., Taylor B.B.J., et all.Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991; 66: 160- 65. Cerca con Google

(52) Oganesyan V., Terzyan S., et all. The crystal structure of the EPCR and a bound phospholipid. J Biological chemistry 2002; 28: 24851-54.. Cerca con Google

(53) Fukudome K., Esmon CT. Molecular cloning and expression of murine and bovine endothelial cell protein c /activated protein c receptor (EPCR). J Biol Chem.1995; 270:5571-5577 Cerca con Google

(54) Fukudome K , Kurusawa S.,et all. The endothelial cell protein c receptor cell surface expression and direct ligand binding by the soluble receptor.J Biol Chem 1996;271:17491-17498 Cerca con Google

(55) Esmon C.T., et all. The protein c pathway : new insights. Thromb Haemost 1997; 78:70-74 Cerca con Google

(56) Fukudome K., Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein c /activated protein c receptor (EPCR). J Biol Chem 1994, 269:24486-91. Cerca con Google

(57) Regan L. M, et all. The endothelial cell protein c receptor . Inibition of activated protein c anticoagulant function without modulation of reaction with protein inhibition.J Biol Chem 1996;271:17499-17503 Cerca con Google

(58) Mammen E. F.. The haematological manifestatios of sepsis. JAC 1998;41(suppl) :17-24. Cerca con Google

(59) Fourrier F., Chopin C et all. Septic shock, MOF,DIC. Compared patterns of ATIII, PC, and protein S deficiens. Chest 1992,101.816/823. Cerca con Google

(60) Taylor Jr F.B., Emerson Jr R.E., Jordan R., Chang A.K.,Blick K.E. Antithrombin-III prevents the lethal effects of Escherichia Coli infusion in baboons . Circ Shock 1988;26:227-35. Cerca con Google

(61) Fourrier F., Chopin C et all. Septic shock, MOF,DIC. Compared patterns of ATIII, PC, and protein S deficiens. Chest 1992,101.816/823. Cerca con Google

(62) Dickneite G., Leithauser B. Influence of ATIII on coagulation and inflammation in porcine septic shock. Arterioscler Thromb vasc Biol 1999; 19:1566-1572. Cerca con Google

(63) Levi M., de Jongue E., et all. Rationale for restoration of physiological anticoagulant pathway in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29:S:90- 4. Cerca con Google

(64) Opal S.M. Therapeutic rationale for antithrombin in sepsis. Crit Care Med 2000; 28S:34-7. Cerca con Google

(65) Blauhut B., Kramar H., Vinazzer H.,bergmann H. Substitution of ATIII in shock and DIC: a randomized study. Thromb Res 1985;39: 81-9. Cerca con Google

(66) BaudoF, Caimi TM et all. ATIII replacement therapy in patients with sepsisand/or postsurgical complcation: a controlled double-blind, randomized, multicenter sudy. Intesive Care Med 1998;24:336-42 Cerca con Google

(67) Balk r., Bedrosian c, et all. Prospective, double-blind,placebo controlled,trial of ATIII substitution in severe sepsis. Intesive Care Med 1995; 2(suppl):517 Cerca con Google

(68) Warren BL, et all. Higt-dose ATIII in severe sepsis a randomized- controlled trial. JAMA 2001;286:1869-78 Cerca con Google

(69) Hitendra S., Schmidz a., et all. Structure function analysis of the reactive site in the first Kunitz-type domain of human TFPI-2. J Biological chemistry 2004;17:17500-17507. Cerca con Google

(70) Creasey A. New potential therapeutic modalities: TFPI. Sepsis 1999;3:173-82. Cerca con Google

(71) La Rosa S. P., Opal S.M. Tissue Factor Pathway Inibitor and Antithrombin Trial results. Crit Care Clin 2005;21:433-48. Cerca con Google

(72) Riewald M., Ruf. Mechanistic coupling of protease signaling and initiaton of coagulation by TF. Proc Natl Acad Sci USA 2001;98(14):7742-7. Cerca con Google

(73) Senden N.H.M., et all. Factor Xa induces cytochine production and expression of adhesion molecules by human ombilical vein endothelial cells. J Immunol 1998; 161:4318-24 Cerca con Google

(74) Schaeffer P., Mares A.M., et all. Coagulation factor Xa induces endothelium-dependent relaxation in rat aorta. Cir Res 1997;81:824-8. Cerca con Google

(75) Creasy A., Chang A.C.K., et all.TFPI reduces mortality from Esherichia Coli septic shock. J Clin Invest 1993;91:2850-60. Cerca con Google

(76) La Rosa S. P., Opal S.M. Tissue Factor Pathway Inibitor and Antithrombin Trial results. Crit Care Clin 2005;21:433-48. Cerca con Google

(77) Creasey A. Reinhart K. TFPI activity in sepsis. Crir Care Med 2001; 29 (suppl):S126-9. Cerca con Google

(78) Gando S., kameue T., et all. TF production not balanced by TFPI in sepsis promotes poor prognosis. Crit Care Med 2002;30:1729-34. Cerca con Google

(79) Eling M., Stephens A.C., et all. TFPI level in the plasma and urine of children with meningococcal disease. Thromb Haemost 2001;85:240-4. Cerca con Google

(80) Opal S., Wunderink R., Laterre P.F. Therapeutical rationale for tissue factor pathway inibitor for severe community-acquired pneumonia (CAP) In: Final program and abstracts of 42° annual meeting Infectious Disease Society of America. Boston: 2004. p.76 Cerca con Google

(81) Enjyoji K., Miyata T., et all. Effect of heparin on the inibition of factor Xa by TFPI : a segment Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995; 34:5725-35. Cerca con Google

(82) Hansen J.B., Sandset P.M. Differentatial effects of low molecular weight and unfractionated heparin on circulating levels of antithrombin and TFPI : a possible mechanismfor difference in therapeutic efficacy.Thromb Res 1998;91:177-8. Cerca con Google

(83) Kemme M.J.B., Burggraaf J. Qualification of heparin-induced TFPI release: a maximum release at low heparin dose. Br j Clin Pharmacol 2002;54:627-34. Cerca con Google

(84) Iba T., Kidokoro A., Fukunaga M., et all. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005;1:25-29 Cerca con Google

(85) Martinez J., Cid A.R., et all. Treatment of intra-abdominal bleeding with recombinant activated factor VII a patients with DIC secondary to septic shock. Blood Coagul Fibrinolysis 2005;16:297- 99. Cerca con Google

(86) Chuansumrit A., Tangnararatchakit K.,et all.The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue shock syndrom. Blood Coagul Fibrinolysis 2004; 15:335-42. Cerca con Google

(87) Hoffman J. N., Vollmar B.,et all. Effect of long-term and high-dose ATIII supplementation on coagulation and fibrinolysis in patiens with severe sepsis. Crit Care Med 2004;32 (9):1851-1859 Cerca con Google

(88) de Pont A.C., et all. Ricombinant human activated protein C reset thrombin generation in patiens with severe sepsis- acase control. Critical Care 2005; ):R490-7 Cerca con Google

(89)Dhainaut JF et all. Soluble thrombomodulin , plasma-derived unactivated protein C and rhAPC. Crit Care Med 2002; 30(5 suppl):S318-324 Cerca con Google

(90) de Jonge E, Levi M. Current drugs treatmebnt strategies for disseminated intravscular coagulation. Drugs 1998;55:767-777. Cerca con Google

(91) Hovinga JA K. Adamts13, vWF and related parameters in severe sepsis and septic shock. J Thromb Haemostasis 2007 Cerca con Google

(92) Furlan M, et al. VWF-cleavivg proteasi in TTP and HUS. NEJM 1998;339:1578-84 Cerca con Google

(93) Tsai .Antibodies to VWF-cleaving protease in acute TTP. NEJM 1998;339:1585-94) Cerca con Google

(94) Mannucci PM. Changes in health and disease of metallo-proteasethat cleaves VWF. Blood 2001,98:2730-2735 Cerca con Google

(95) Bernardo. Effects of imnflammatory cytochines on the release and cleavage of the endothelial cell- derived ultralarge VWF multimers under flow.Blood 2004;104:100-106 Cerca con Google

(96) Nasqvi T.A. et al. Post-operative TTP a review. Int J clin Pract 2004; 58: 169-172) Cerca con Google

(97) Stephan F., Cheffi M.A., Kaplan C.. Autoantibodies against platelet glycoproteins in critically ill patiens with thrombocytopenia. Am J Med 2000; 108: 554-60 Cerca con Google

(98) Mori M., kudo H., Yoshitake S transient EDTA-dependentpseudothrombocytopenia in patiens with sepsis. Intensive Care Med 2000; 26:218-220. Cerca con Google

(99) Francois B., Trimoreau F., vignon P. Thrombocytopenia in sepsis syndrome : role of hematophagocytosis and macrophage colony-stimulating factor. Am J Med 1997; 103: 114-120. Cerca con Google

(100) Sawaki D. MD, Yoshitaka O., et all. A case of Heparin- Inducee Thrombocytopenia with sepsis and congestive Heart failure. Circ J 2004;68:1215-1218. Cerca con Google

(101) Vanderschueren S., De Weerdt A.. Thrombocythopenia and prognosis in intensive care. Critical Care Med 2000; 28: 1871-1876. Cerca con Google

(102) Gary T., Kinasewitz M.D., et all. Prognostic value of simple envolving DIC score in patiens with severe sepsis. Crit Care Med 2005; 33:2214-2221. Cerca con Google

(103) Sjöbring U, Ringdhal U, Ruggeri ZM. Induction of platelet thrombi by bacteria and antibodies. Blood 2002;100:4470-4477 Cerca con Google

(104) White B., Perry D.. Acquired antithrombin deficiency in sepsis. Br J haematol 2001, 112: 26-31. Cerca con Google

(105) Eisele B., Lamy M..Antithrombin III in patiens with severe sepsis: a randomized, placebocontrolled, double-blind multicenter trial plus a meta-analysis on all randomized, placebocontrolled, double-blind trials with Antithrombin III in severe sepsis. Intesive Care Med 1998;24:663-72. Cerca con Google

(106) Opal S.M., fisher Jr C. J., Dhainaut J.F.. Confirmatory IL-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trials. Crir Care Med 1997;25:1115-24. Cerca con Google

(107) Wang P., Wood T.J.et all. Inhibition of the biological activity of TNF mantains vascular endothelial cell function during hyperdynamic sepsis. J Trauma 1996; 40: 694-71. Cerca con Google

(108) Bauer P.R. Microvascular responses to sepsis: clinical significance. Pathophysiology 2002; 8:141- 148. Cerca con Google

(109) Ratnoff O.D., Nebehay W.G.. Multiple coagulative defects in patiens with the Waterhouse- Friderihsen syndrome. Ann Inter Med 1962; 56: 627-630. Cerca con Google

(110) Shimamura K., Oka K., Nakazawa M.. Distribuition patterns of microthrombi in DIC. Arch Pathol Lab Med 1983; 107:543-7. Cerca con Google

(111) Wolff B. Endothelial cell memory of inflammatory stimulation. Human venular endothelial cells store IL8 in Weibel-Palade bodies. J Exp Med 1998;188:1757-1762 Cerca con Google

(112) Utgaard JO . Rapid secretion of prestored IL8 from Weibel-Palade bodies of microvascular endothelial cells. J Exp Med 1998;188:1751-1756). Cerca con Google

(113) Tomolo ono, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced dissiminated intravascular coagulation: its correlation with developement of renal failure. Blood 2006;107.528-534. Cerca con Google

(114) Hack CE, et al. Role of cytochines in sepsis. Adv immunol 1997;66:101-195 Cerca con Google

(115) Consensus document ACCP/SCCM Crit Care Med 1992;20:864-874 Cerca con Google

(116) Z.M. Ruggeri. Prospectives series: cell adhesion in vascular biology.J. Clin. Invest.1997; 99: 559- 564 Cerca con Google

(117) Ruggeri ZM. Structure and function of VWF. Thromb Haemost. 1992;67:594-99 Cerca con Google

(118) Ohomori K. Electron microscopy of human factor VIII/VWglycoprotein : effect of reducing reagents on structure and function . J Cell Biol 1982; 95:632-640. Cerca con Google

(119) Counts RB. Disulfide bond and quaternary structure of factor VIII/VWF. J. Clin Invest 1978;62:702-709. Cerca con Google

(120) Gralnick HR. effect of multimeric structure of factor VIII/VWF protein on binding to platelets. Blood 1981;58:387-397) Cerca con Google

(121) Van Mourick el al. VWF propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94:179-185 Cerca con Google

(122) Casonato A et al Reduced VWF survival in type Vicenza von Willebrand desease. Blood 2002; 99:180-184 Cerca con Google

(123) Furlan . Partial purification and characterization of proteasi from human plasma cleaving VWF to fragment produced by in vivo proteolisis. Blood 1996;87:4223-4234 Cerca con Google

(124) Tsai HM. A journey from sickle cell anemia to ADAMTS13. J Thromb Haemost 2004;2:1510-1514 Cerca con Google

(125) Arya M. Ultralarge multimers of VWF form spontaneous high-strengh bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002;99:3971-77 Cerca con Google

(126) Levy. Mutations in a memmber of ADAMTS gene family cause TTP. Nature 2001;413:488-50 Cerca con Google

(127) Furlan. Deficient activity of VWF-cleaving protease in chronic relapsing TTP. Blood 1997;89:3097-3103 Cerca con Google

(128) Dong J et al. Adamts 13 cleaves newly secreted ultralarge vWF multimers on the endothelial surface under flowing condictions. Blood 2002;100:4033-4039. Cerca con Google

(129) Andersen. Support of ristocetin-induced platelet aggregation by procoagulant-inactive and plasmincleaved form of human Fact VIII/VWF.Blood 1980;55:101-108 Cerca con Google

(130) Howard RJ . Cleavage of human VWF by porcine pancreatic elastasi. Blood 1989;74:673-678 Cerca con Google

(131) Kunicki TJ Cleavage of human VWF by platelet calcium-activated. Blood 1985;65:352) Cerca con Google

(132) Padilla A. P-selectin anchors newly released ultralarge VWF multimers to the endothelial cellsurface. Blood 2004; 103:2150-56. Cerca con Google

(133) Dong J et al. Adamts 13 cleaves newly secreted ultralarge vWF multimers on the endothelial surface under flowing condictions. Blood 2002;100:4033-403 Cerca con Google

(134) Shang . Apical sorting of l’ADAMTS13 in vascular endothelial cells and Madin-Darby caninekidney cells depends on the CUB domains and their association with lipid raft .Blood 2006:7; 2207- 2215 Cerca con Google

(135) Moake JL Thrombotic microangiopathy NEJM 2002; 347:589-600 Cerca con Google

(136) Sadler JE . A new name in thrombosis ADAMTS13.PNAS 2002;99:11552-11554 Cerca con Google

(137) Dong JF, Moake JL. ADAMTS13 rapidy cleaves newly secreted ultralarge VWF multimers on the endothelial surface under flowing condiction. Blood 2002;5:1401 Cerca con Google

(138) Savage B, Ruggeri ZM. Cell 1998;94;657-666 Cerca con Google

(139) Matsumoto M. Molecular characterization of ADAMTS13 gene mutation in Japanese patients with Upshaw-Schulman Sindrome. Blood 2004,103:1305-1310 Cerca con Google

(140) Litch C. Two novel . ADAMTS13 gene mutation in TTP/HUS. Kidney Int 2004;66:955-958 Cerca con Google

(141) Kokame K. Mutations and common polymorphism in ADAMTS13 gene responsible for VWFcleaving protease activity. Proc natl Acad Sci USA. 2002;99:11902-11907 Cerca con Google

(142) Levy. ADAMTS13 turns 3. Blood 2005;106:11-17 Cerca con Google

(143) Banno F. Complete deficiency in ADAMTS13 is prothrombotic, but alone is not sufficient to causes TTP. Blood 2006; 8:3161-3166 Cerca con Google

(144) Lattuada A. Mild to moderate reduction of vWF cleaving protease (ADAMTS13) in pregnant women with HELLP microangiotathic sindrome. Haematologica 2003;88:1029-34 Cerca con Google

(145) Egerman RS. HELLP sindrome. Clin Obstet Gynecol 1999;42:381-9 Cerca con Google

(146) Mannucci PM VWF cleaving protese (ADAMTS13) in 123 patients with connective tissue disease systemic lupus erytematosus and systemic sclerosis. Haematologica 2003;88:914-918 Cerca con Google

(147) Barbot J. Ten years of prophylatic treatment with fresh frozen plasma in a child with cronic relapsing thrombotic thrombocytopenic purpura as the result of a congenital deficiency of VWF cleaving protese.Br J Haematol 2001;113:649-51 Cerca con Google

(148) Gorge JN. Familiar acquired thrombotic thrombocytopenic purpura: ADAMTS13 inibitory autoatibodies in idetical twins. Blood 2004;103:4195-4197 Cerca con Google

(149) Furlan M. Acquired deficiency of VWF-cleaving proteae in a patient with TTP. Blood 1998;91:2839-46 Cerca con Google

(150) Colman RW Hemostasis and thrombosis . Fifth ediction LWW. Cerca con Google

(151) Kitchens.Consultative Hemostasis and thrombosis Saunders.Second ediction 2007. Cerca con Google

(152) Sterling T. Bennett. Laboratory Hemostasis. Springer 2007 Cerca con Google

(153) Rivers E., McIntyre L., et all. Early and inovative interventions for severe sepsis and septic shock: taking advantage of window of opportunity. CMAJ 2005;25: 1054-1065. Cerca con Google

(154) Monnet X., Lamia B., Anguel N., et all. Rapid and beneficial hemodynamic effects of activated protein C in septic shock patiens. Int Care Med 2005; 31:1573-1576. Cerca con Google

(155) Vincent J. L., De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care Med 2005;9 (suppl 4):S-9-S12. Cerca con Google

(156) Dhainaut J-F. Re-estabilishing organ function in severe sepsis: targeting the microcirculation. Crit Care 2005, 9(suppl-4):S1-S2. Cerca con Google

(157) Brown G. Coagulation cascate in sepsis: getting from bench to beside? Critical Care 2003;7:117- 118. Cerca con Google

(158) Slade E., et all. The surviving sepsis csmpaign: raising awareness to reduce mortality. Critical Care 2003; 7:1-2. Cerca con Google

(159) Markou N., Apostolakos H., et all. Itravenous colistin in the treatment of sepsis from multiresistat Gram-negative bacilli in crtically ill patients. Crit Care 2003; 7: R78-R-83. Cerca con Google

(160) Arabi Y., Al Shirawi N. ,et all. Assessment of six mortality prediction models in patients admitted with severe sepsis and septic shock to the intensive care unit: a prospective cohort study. Crit Care 2003; 7:R116-R122. Cerca con Google

(161) Esmon C. T. : Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 2004; 32, 5: S219-222. Cerca con Google

(162) Johnson K, Choi Y., De Groot E ., et all. Potential mechanism for a proinflammatory vascular cytokine response to coagulation activation. The Journal of Immunology 1998; 23: 5130-35. Cerca con Google

(163) Freeman B.D. , Zehnbauer B. A., Buchman T. G. A meta-analisis of controlled trials of anticoagulant therapies in patiens with sepsis. Shock 2003 20;5-9. Cerca con Google

(164) Sawaki D. MD, Yoshitaka O., et all. A case of Heparin- Inducee Thrombocytopenia with sepsis and congestive Heart failure. Circ J 2004;68:1215-1218. Cerca con Google

(165) O’ Brien J. M., Abraham E: Human models of endotoxemia and recombinant human activated protein C. Crit Care Med 2004; 32, 5: S202-208. Cerca con Google

(166) Mesters R. M., Mannuccci P. M., Coppola et all. Factor VIIa and ATIII activity during severe sepsis and septic shock in neutropenic patiens. Blood 1996;88: 881-886. Cerca con Google

(167) Seita R., Wolf M., Egbring R., et all. The disturbance of hemostasis in septic shock: role of neutrophil and elastase and thrombin,effects of antithrombin III and plasma substitution. Eur J Haematol 1989;43.22-8. Cerca con Google

(168) White B., Perry D.. Acquired antithrombin deficiency in sepsis. Br J haematol 2001, 112: 26-31. Cerca con Google

(169) Zeerlerder S., Hack C. E., Wuillemin W. A. Disseminated Intravascular coagulation in sepsis. Chest 2005; 24:2864-2875. Cerca con Google

(170) Critical Care Clinnics 2005;21:3 GUEST EDITORS Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record